MIRA Pharmaceuticals

MIRA Pharmaceuticals (NASDAQ: MIRA), formerly MIRA1a Therapeutics, is a Miami, Florida-based clinical-stage pharmaceutical company (incorporated 2020, IPO August 2023) developing oral small-molecule therapies for neurologic, neuropsychiatric, and metabolic disorders. Its pipeline includes Ketamir-2, a next-generation oral NMDA receptor modulator with exclusive US, Canadian, and Mexican rights that has completed Phase 1; MIRA-55, an oral non-opioid candidate for chronic inflammatory and neuropathic pain advancing toward IND-enabling studies (7-day toxicology and PK studies completed July 2026); and SKNY-1, a preclinical candidate for obesity and nicotine dependence. On July 27, 2026 the company received a Nasdaq notice of non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.